226 related articles for article (PubMed ID: 10854138)
21. Patterns of lymphotropic herpesvirus viraemia in HIV-infected patients with Kaposi's sarcoma treated with highly active antiretroviral therapy and liposomal daunorubicin.
Torre-Cisneros J; Pozo F; Serrano R; Vidal E; Rivero A; Tenorio A
AIDS; 2000 Sep; 14(14):2215-7. PubMed ID: 11061671
[No Abstract] [Full Text] [Related]
22. Liposomal daunorubicin is not recommended in patients with less than advanced HIV-related Kaposi's sarcoma.
White RM
AIDS; 1997 Sep; 11(11):1412-3. PubMed ID: 9302461
[No Abstract] [Full Text] [Related]
23. Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults.
Ribera E; Lopez RM; Diaz M; Pou L; Ruiz L; Falcó V; Crespo M; Azuaje C; Ruiz I; Ocaña I; Clotet B; Pahissa A
Antimicrob Agents Chemother; 2004 Nov; 48(11):4256-62. PubMed ID: 15504850
[TBL] [Abstract][Full Text] [Related]
24. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study.
Périard D; Telenti A; Sudre P; Cheseaux JJ; Halfon P; Reymond MJ; Marcovina SM; Glauser MP; Nicod P; Darioli R; Mooser V
Circulation; 1999 Aug; 100(7):700-5. PubMed ID: 10449690
[TBL] [Abstract][Full Text] [Related]
25. Prospective stage-stratified approach to AIDS-related Kaposi's sarcoma.
Bower M; Dalla Pria A; Coyle C; Andrews E; Tittle V; Dhoot S; Nelson M
J Clin Oncol; 2014 Feb; 32(5):409-14. PubMed ID: 24378415
[TBL] [Abstract][Full Text] [Related]
26. Health-related quality of life in HIV patients switching to twice-daily indinavir/ritonavir regimen or continuing with three-times-daily indinavir-based therapy.
Badía X; Podzamczer D; Moral I; Roset M; Arnaiz JA; Loncà M; Casiró A; Rosón B; Gatell JM;
Antivir Ther; 2004 Dec; 9(6):979-85. PubMed ID: 15651756
[TBL] [Abstract][Full Text] [Related]
27. FDA approves DaunoXome as first-line therapy for Kaposi's sarcoma. Food and Drug Administration.
J Int Assoc Physicians AIDS Care; 1996 May; 2(5):50-1. PubMed ID: 11363534
[TBL] [Abstract][Full Text] [Related]
28. Pharmacology of liposomal daunorubicin and its use in Kaposi's sarcoma.
Chew T; Jacobs M
Oncology (Williston Park); 1996 Jun; 10(6 Suppl):28-33; discussion 37-8. PubMed ID: 16871707
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic drug monitoring of saquinavir in patients during protease inhibitor therapy with saquinavir alone or in combination with ritonavir or nelfinavir.
Langmann P; Zilly M; Weissbrich B; Schlör C; Väth T; Richter E; Klinker H
Eur J Med Res; 2000 Feb; 5(2):59-62. PubMed ID: 10720564
[TBL] [Abstract][Full Text] [Related]
30. Randomized cross-over comparison of liposomal daunorubicin versus observation for early Kaposi's sarcoma.
Uthayakumar S; Bower M; Money-Kyrle J; Muyshondt C; Youle M; Hannon F; Phillips R; Gazzard BG; Boag F
AIDS; 1996 May; 10(5):515-9. PubMed ID: 8724043
[TBL] [Abstract][Full Text] [Related]
31. Kaposi's-sarcoma-associated herpesvirus is detected in peripheral blood mononuclear cells of HIV-infected homosexuals more often than in heterosexuals.
Rizzieri DA; Liu J; Miralles D; Traweek ST
Cancer J Sci Am; 1997; 3(3):153-6. PubMed ID: 9161780
[TBL] [Abstract][Full Text] [Related]
32. Administration of indinavir and low-dose ritonavir (800/100 mg twice daily) with food reduces nephrotoxic peak plasma levels of indinavir.
Aarnoutse RE; Wasmuth JC; Fätkenheuer G; Schneider K; Schmitz K; de Boo TM; Reiss P; Hekster YA; Burger DM; Rockstroh JK
Antivir Ther; 2003 Aug; 8(4):309-14. PubMed ID: 14518700
[TBL] [Abstract][Full Text] [Related]
33. Clinical and pharmacokinetic data support once-daily low-dose boosted saquinavir (1,200 milligrams saquinavir with 100 milligrams ritonavir) in treatment-naive or limited protease inhibitor-experienced human immunodeficiency virus-infected patients.
Marin-Niebla A; Lopez-Cortes LF; Ruiz-Valderas R; Viciana P; Mata R; Gutierrez A; Pascual R; Rodriguez M
Antimicrob Agents Chemother; 2007 Jun; 51(6):2035-42. PubMed ID: 17371813
[TBL] [Abstract][Full Text] [Related]
34. Regression of AIDS-related Kaposi's sarcoma following combined antiretroviral treatment.
Monticelli A; Lewi D; Salomon H; Pampuro S; Libonatti O; Jauregui Rueda H; Hodara V
Rev Argent Microbiol; 2000; 32(4):206-8. PubMed ID: 11149154
[TBL] [Abstract][Full Text] [Related]
35. The choice of HIV protease inhibitor: indinavir is currently the best option.
Prescrire Int; 1999 Apr; 8(40):55-60. PubMed ID: 10848067
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.
Ribera E; Azuaje C; Lopez RM; Domingo P; Curran A; Feijoo M; Pou L; Sánchez P; Sambeat MA; Colomer J; Lopez-Colomes JL; Crespo M; Falcó V; Ocaña I; Pahissa A
J Antimicrob Chemother; 2007 Apr; 59(4):690-7. PubMed ID: 17307771
[TBL] [Abstract][Full Text] [Related]
37. Extravasation of liposomal daunorubicin in patients with AIDS-associated Kaposi's sarcoma: a report of four cases.
Cabriales S; Bresnahan J; Testa D; Espina BM; Scadden DT; Ross M; Gill PS
Oncol Nurs Forum; 1998; 25(1):67-70. PubMed ID: 9460774
[TBL] [Abstract][Full Text] [Related]
38. Treatment of HIV-1-associated Kaposi's sarcoma with pegylated liposomal doxorubicin and HAART simultaneously induces effective tumor remission and CD4+ T cell recovery.
Lichterfeld M; Qurishi N; Hoffmann C; Hochdorfer B; Brockmeyer NH; Arasteh K; Mauss S; Rockstroh JK;
Infection; 2005 Jun; 33(3):140-7. PubMed ID: 15940415
[TBL] [Abstract][Full Text] [Related]
39. Liposomal KS drugs approved.
GMHC Treat Issues; 1996 Apr; 10(4):8-9. PubMed ID: 11363710
[TBL] [Abstract][Full Text] [Related]
40. Phase II studies with DaunoXome in patients with nonresectable hepatocellular carcinoma: clinical and pharmacokinetic outcomes.
Yeo W; Chan KK; Mukwaya G; Ross M; Leung WT; Ho S; Chan AT; Johnson PJ
Cancer Chemother Pharmacol; 1999; 44(2):124-30. PubMed ID: 10412946
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
